Achieving “Progress” in Progressive Multiple Sclerosis: Advances in Therapy

Clinical Care Options (CCO) downloadable slideset of faculty expert and a patient with MS discussing therapies for progressive MS and management of MS symptoms

Daniel Kantor, MD, FAAN
Program Director Shirley Nedzesky Released: November 15, 2021

Listen to one of the world’s leading experts discuss the future of pharmacotherapies for psychiatric disorders. Earn 1 hour of CME/CE credit for free in this online webcast.

Greg W. Mattingly, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits Released: March 15, 2020 Expired: No longer available for credit

Multiple sclerosis (MS) is a progressive disease of the central nervous system. It affects approximately 1 million people in the US and is most commonly diagnosed between the ages of 20 and 50 years, largely in women. MS causes a variety of motor and nonmotor symptoms and can have devastating effects on productivity and quality of life. This program will review the signs and symptoms of MS to best facilitate early referral for comprehensive neurologic work-up and initiation of disease-modifying therapy (DMT). It will also discuss the primary care clinician’s role in coordinating care, counseling on DMT adherence, and managing the comorbidities of MS.

Mary Knudtson, DNSc, NP, FAAN Claire Riley, MD Released: January 24, 2020